NICE should reconsider osteoporosis guidance say 40 experts
By Nigel Praities
NICE must reconsider its ‘unworkable' guidance on osteoporosis and allow greater access to alternative treatments to alendronate, says a letter signed by 40 clinical leaders published in The Times.
The letter comes as NICE holds a second appeal hearing on technology appraisals for the primary and secondary prevention of osteoporosis that were begun six years ago and are still not completed.
The signatories say the appraisals are ‘unethical and short-sighted', restricting access to alendronate and other alternatives to prevent fractures until their osteoporosis has become significantly worse.
‘Over the next few weeks NICE will have the opportunity to put this right. We hope that this time around the opportunity is grasped with both hands so that we can then all pursue a more enlightened approach to the management of osteoporosis,' the letter reads.